Targeting translation: EIF4E as an emerging anticancer drug target

Chunwan Lu, Levi Makala, Daqing Wu, Yafei Cai

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


The translation initiation factor eIF4E mediates a rate-limiting process that drives selective translation of many oncongenic proteins such as cyclin D1, survivin and VEGF, thereby contributing to tumour growth, metastasis and therapy resistance. As an essential regulatory hub in cancer signalling network, many oncogenic signalling pathways appear to converge on eIF4E. Therefore, targeting eIF4E-mediated cap-dependent translation is considered a promising anticancer strategy. This paper reviews the strategies that can be used to target eIF4E, highlighting agents that target eIF4E activity at each distinct level.

Original languageEnglish (US)
Article numbere2
JournalExpert Reviews in Molecular Medicine
StatePublished - Jan 18 2016

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Targeting translation: EIF4E as an emerging anticancer drug target'. Together they form a unique fingerprint.

Cite this